ULTRAGENYX PHARMACEUTICAL INC. Acquisitions, Net of Cash Acquired
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2025-02-19
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire businesses, net of cash acquired for the quarter ending 2023-12-31 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was -$366.00K.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire businesses, net of cash acquired for the quarter ending 2021-12-31 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire businesses, net of cash acquired for fiscal 2024 was $0.00.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire businesses, net of cash acquired for fiscal 2022 was $75.03M.
- ULTRAGENYX PHARMACEUTICAL INC. payments to acquire businesses, net of cash acquired for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-19 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 10-K · filed 2025-02-19 | |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-03 | ||
| 2022-12-31 | -$366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $75.03M 10-K · filed 2025-02-19 | |
| 2022-09-30 | $75.39M 10-Q · filed 2023-11-03 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 10-K · filed 2024-02-21 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-17 | ||
| 2017-12-31 | $142.80M 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |